Jefferies Group LLC reiterated their buy rating on shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in a research report sent to investors on Friday morning. They currently have a $15.00 target price on the specialty pharmaceutical company’s stock.

A number of other equities analysts also recently issued reports on the company. HC Wainwright began coverage on Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a buy rating and a $21.00 price target on the stock. Piper Jaffray Companies restated a buy rating and issued a $14.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, September 8th. Zacks Investment Research upgraded Collegium Pharmaceutical from a sell rating to a hold rating in a research note on Monday, August 14th. BidaskClub cut Collegium Pharmaceutical from a hold rating to a sell rating in a report on Friday, August 4th. Finally, ValuEngine raised Collegium Pharmaceutical from a strong sell rating to a sell rating in a report on Thursday, June 22nd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company presently has a consensus rating of Hold and a consensus price target of $20.00.

Shares of Collegium Pharmaceutical (NASDAQ COLL) traded up 3.60% during mid-day trading on Friday, hitting $11.79. The company’s stock had a trading volume of 993,394 shares. Collegium Pharmaceutical has a 52-week low of $9.27 and a 52-week high of $18.67. The company’s market cap is $348.58 million. The stock’s 50 day moving average price is $10.53 and its 200 day moving average price is $10.53.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.81) by $0.09. The firm had revenue of $3.56 million for the quarter, compared to the consensus estimate of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. Equities analysts forecast that Collegium Pharmaceutical will post ($3.00) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Collegium Pharmaceutical, Inc. (COLL) Given Buy Rating at Jefferies Group LLC” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-given-buy-rating-at-jefferies-group-llc/1616208.html.

A number of large investors have recently bought and sold shares of the business. California State Teachers Retirement System raised its holdings in Collegium Pharmaceutical by 21.5% during the second quarter. California State Teachers Retirement System now owns 40,195 shares of the specialty pharmaceutical company’s stock valued at $503,000 after acquiring an additional 7,100 shares during the period. The Manufacturers Life Insurance Company raised its holdings in Collegium Pharmaceutical by 38.4% during the second quarter. The Manufacturers Life Insurance Company now owns 18,621 shares of the specialty pharmaceutical company’s stock valued at $233,000 after acquiring an additional 5,167 shares during the period. State Street Corp raised its holdings in Collegium Pharmaceutical by 17.7% during the second quarter. State Street Corp now owns 321,340 shares of the specialty pharmaceutical company’s stock valued at $4,025,000 after acquiring an additional 48,236 shares during the period. Macquarie Group Ltd. raised its holdings in Collegium Pharmaceutical by 37.1% during the second quarter. Macquarie Group Ltd. now owns 1,118,691 shares of the specialty pharmaceutical company’s stock valued at $13,995,000 after acquiring an additional 302,892 shares during the period. Finally, Royal Bank of Canada raised its holdings in Collegium Pharmaceutical by 12.7% during the second quarter. Royal Bank of Canada now owns 29,139 shares of the specialty pharmaceutical company’s stock valued at $365,000 after acquiring an additional 3,285 shares during the period. 83.04% of the stock is currently owned by institutional investors and hedge funds.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Analyst Recommendations for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.